Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.

The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is activated in cancer due to mutations in RAS proteins (especially KRAS), BRAF, CRAF, MEK1 and MEK2. Whilst inhibitors of KRASG12C (lung adenocarcinoma) and BRAF and MEK1/2 (melanoma and colorectal cancer) are clinically approved, acquired resistance remains a problem. Consequently, the search for new inhibitors (especially of RAS proteins), new inhibitor modalities and regulators of this pathway, which may be new drug targets, continues and increasingly involves cell-based screens with small molecules or genetic screens such as RNAi, CRISPR or protein interference. Here we describe cell lines that exhibit doxycycline-dependent expression KRASG12V or BRAFV600E and harbour a stably integrated EGR1:EmGFP reporter gene that can be detected by flow cytometry, high-content microscopy or immunoblotting. KRASG12V or BRAFV600E-driven EmGFP expression is inhibited by MEK1/2 or ERK1/2 inhibitors (MEKi and ERKi). BRAFi inhibit BRAFV600E-driven EmGFP expression but enhance the response to KRASG12V, recapitulating paradoxical activation of wild type RAF proteins. In addition to small molecules, expression of iDab6, encoding a RAS-specific antibody fragment inhibited KRASG12V- but not BRAFV600E-driven EmGFP expression. Finally, substitution of EmGFP for a bacterial nitroreductase gene allowed KRASG12V or BRAFV600E to drive cell death in the presence of a pro-drug, which may allow selection of pathway inhibitors that promote survival. These cell lines should prove useful for cell-based screens to identify new regulators of KRAS- or BRAF-dependent ERK1/2 signalling (drug target discovery) as well as screening or triaging 'hits' from drug discovery screens.

Perceptual addition of continuous magnitudes in an 'artificial algebra'.

Although there is substantial evidence for an innate 'number sense' that scaffolds learning about mathematics, whether the underlying representations are based on discrete or continuous perceptual magnitudes has been controversial. Yet the nature of the computations supported by these representations has been neglected in this debate. While basic computation of discrete non-symbolic quantities has been reliably demonstrated in adults, infants, and non-humans, far less consideration has been given to the capacity for computation of continuous perceptual magnitudes. Here we used a novel experimental task to ask if humans can learn to add non-symbolic, continuous magnitudes in accord with the properties of an algebraic group, by feedback and without explicit instruction. Three pairs of experiments tested perceptual addition under the group properties of commutativity (Experiments 1a-b), identity and inverses (Experiments 2a-b) and associativity (Experiments 3a-b), with both line length and brightness modalities. Transfer designs were used in which participants responded on trials with feedback based on sums of magnitudes and later were tested with novel stimulus configurations. In all experiments, correlations of average responses with magnitude sums were high on trials with feedback. Responding on transfer trials was accurate and provided strong support for addition under all of the group axioms with line length, and for all except associativity with brightness. Our results confirm that adult human subjects can implicitly add continuous quantities in a manner consistent with symbolic addition over the integers, and that an 'artificial algebra' task can be used to study implicit computation.

Range and distribution effects on number line placement.

People's placement of numbers on number lines sometimes shows linear and sometimes compressive scaling. We investigated whether people's placement of numbers was affected by their range and distribution, as indicated by Parducci's (Psychological Review, 72, 407-418, 1965) range-frequency theory. Experiment 1 found large compressive effects when the endpoints were 1 and 1016. Experiment 2 showed compression when 14 logarithmically distributed numbers were placed on a line marked 1-1,000 and close to linear scaling when the numbers were linearly distributed. Thus, we found both range and frequency effects on compression. Where compression arose, it was not as pronounced as that predicted by logarithmic scaling, but analyses of the results from Experiments 1 and 2 indicate this was not explained by participants switching between linear and logarithmic scaling.

Localized inhibition of platelets and platelet derived growth factor by a matrix targeted glycan mimetic significantly attenuates liver fibrosis.

New therapeutic strategies are needed for the growing unmet clinical needs in liver disease and fibrosis. Platelet activation and PDGF activity are recognized as important therapeutic targets; however, no therapeutic approach has yet addressed these two upstream drivers of liver fibrosis. We therefore designed a matrix-targeting glycan therapeutic, SBR-294, to inhibit collagen-mediated platelet activation while also inhibiting PDGF activity. Herein we describe the synthesis and characterization of SBR-294 and demonstrate its potential therapeutic benefits in vitro and in vivo. In vitro SBR-294 was found to bind collagen (EC50 = 23 nM), thereby inhibiting platelet-collagen engagement (IC50 = 60 nM). Additionally, SBR-294 was found to bind all PDGF homodimeric isoforms and to inhibit PDGF-BB mediated hepatic stellate cell activation and proliferation. Translating these mechanisms in vivo, SBR-294 reduced fibrosis by up to 54% in the CCl4 mouse model (p = 0.0004), as measured by Sirius red histological analysis. Additional fibrosis measurements were also supportive of the therapeutic benefit in this model. These results support the therapeutic benefit of platelet and PDGF antagonism and warrant further investigation of SBR-294 as a potential treatment for liver fibrosis.

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.

The ERK1/2 signalling pathway is best known for its role in connecting activated growth factor receptors to changes in gene expression due to activated ERK1/2 entering the nucleus and phosphorylating transcription factors. However, active ERK1/2 also translocate to a variety of other organelles including the endoplasmic reticulum, endosomes, golgi and mitochondria to access specific substrates and influence cell physiology. In this article, we review two aspects of ERK1/2 signalling at the mitochondria that are involved in regulating cell fate decisions. First, we describe the prominent role of ERK1/2 in controlling the BCL2-regulated, cell-intrinsic apoptotic pathway. In most cases ERK1/2 signalling promotes cell survival by activating prosurvival BCL2 proteins (BCL2, BCL-xL and MCL1) and repressing prodeath proteins (BAD, BIM, BMF and PUMA). This prosurvival signalling is co-opted by oncogenes to confer cancer cell-specific survival advantages and we describe how this information has been used to develop new drug combinations. However, ERK1/2 can also drive the expression of the prodeath protein NOXA to control 'autophagy or apoptosis' decisions during nutrient starvation. We also describe recent studies demonstrating a link between ERK1/2 signalling, DRP1 and the mitochondrial fission machinery and how this may influence metabolic reprogramming during tumorigenesis and stem cell reprogramming. With advances in subcellular proteomics it is likely that new roles for ERK1/2, and new substrates, remain to be discovered at the mitochondria and other organelles.

Collagen-binding peptidoglycans inhibit MMP mediated collagen degradation and reduce dermal scarring.

Scarring of the skin is a large unmet clinical problem that is of high patient concern and impact. Wound healing is complex and involves numerous pathways that are highly orchestrated, leaving the skin sealed, but with abnormal organization and composition of tissue components, namely collagen and proteoglycans, that are then remodeled over time. To improve healing and reduce or eliminate scarring, more rapid restoration of healthy tissue composition and organization offers a unique approach for development of new therapeutics. A synthetic collagen-binding peptidoglycan has been developed that inhibits matrix metalloproteinase-1 and 13 (MMP-1 and MMP-13) mediated collagen degradation. We investigated the synthetic peptidoglycan in a rat incisional model in which a single dose was delivered in a hyaluronic acid (HA) vehicle at the time of surgery prior to wound closure. The peptidoglycan treatment resulted in a significant reduction in scar tissue at 21 days as measured by histology and visual analysis. Improved collagen architecture of the treated wounds was demonstrated by increased tensile strength and transmission electron microscopy (TEM) analysis of collagen fibril diameters compared to untreated and HA controls. The peptidoglycan's mechanism of action includes masking existing collagen and inhibiting MMP-mediated collagen degradation while modulating collagen organization. The peptidoglycan can be synthesized at low cost with unique design control, and together with demonstrated preclinical efficacy in reducing scarring, warrants further investigation for dermal wound healing.

The inhibition of platelet adhesion and activation on collagen during balloon angioplasty by collagen-binding peptidoglycans.

Collagen is a potent stimulator for platelet adhesion, activation, and thrombus formation, and provides a means for controlling blood loss due to injury, and recruiting inflammatory cells for fighting infection. Platelet activation is not desirable however, during balloon angioplasty/stent procedures in which balloon expansion inside an artery exposes collagen, initiating thrombosis, and inflammation. We have developed biomimetic polymers, termed peptidoglycans, composed of a dermatan sulfate backbone with covalently attached collagen-binding peptides. The peptidoglycan binds to collagen, effectively masking it from platelet activation. The lead peptidoglycan binds to collagen with high affinity (K(D) = 24 nm) and inhibits platelet binding and activation on collagen in both static studies and under flow, while promoting endothelial regrowth on collagen. Application for angioplasty is demonstrated in the Ossabaw miniature pig by fast delivery to the vessel wall through a therapeutic infusion catheter with a proprietary PTFE porous balloon. The peptidoglycan is an approach for locally preventing platelet deposition and activation on collagen. It can be used during angioplasty to prevent platelet deposition on target vessels and could be used in any vessel, including those not amenable to stent deployment.

Characterization of gels composed of blends of collagen I, collagen III, and chondroitin sulfate.

Type I collagen is explored heavily for use in biomaterials, but the role of other extracellular matrix components in regulating collagen organization is gaining attention. We show that as the ratio of type III to type I collagen increases, fibril diameter decreases. A mixture of the two collagen types results in a more open structural network, corresponding to a more compliant material, as compared to a material composed of only one collagen type. Glycosaminoglycans also affect collagen organization and tissue properties. We show that chondroitin sulfate decreases the collagen fibril diameter. Additionally, chondroitin sulfate (CS) increases the void space of a collagen I or collagen III gel, resulting in a more compliant material, but the interactions between types I and III collagen negate the effects of CS. The simple combination of these components results in materials with unique structural, mechanical, and biological cues that can be useful in tailoring biomaterials for tissue engineering.

Influence of chondroitin sulfate on collagen gel structure and mechanical properties at physiologically relevant levels.

The ability to alter collagen organization could lead to more physiologically relevant scaffolds for tissue engineering. This study examined collagen organization in the presence of polysaccharide and the resulting effects on viscoelastic properties. Fibrillogenesis in the presence of chondroitin sulfate (CS) resulted in changes in the collagen network organization with an increase in void space present. The increased void space caused by CS addition correlated with a decreased stiffness of the collagen gel. These changes occurred with physiologically relevant ratios of collagen to CS, at physiological pH and ionic strength, and without a decrease in the amount of collagen incorporated into fibrils. The addition of dextran, an uncharged polysaccharide, yielded no change in network void space or mechanical properties. Changes in fibril diameter caused by CS or dextran were not correlated with mechanical properties. The results of this study demonstrate that collagen organization can be modified by the addition of GAG, leading to altered matrix mechanical properties.

Preparation of biomolecule gel matrices for electron microscopy.

We report a new sample preparation method that allows the direct transmission electron microscopy evaluation of the architectural characteristics of biomolecules entrapped in gel matrices. We demonstrate that this sample preparation technique can be used for the identification and ultrastructural characterization of liposomes, collagen I and collagen III embedded in gel matrices, and has the potential to be useful for transmission electron microscopy (TEM) characterization of other biomolecule-gel matrix systems.